期刊
CURRENT OPINION IN PHARMACOLOGY
卷 21, 期 -, 页码 115-121出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2015.01.004
关键词
-
资金
- NIH [HL-076803, HL-093186, HL-096830, T32-HL-083810, F32-HL-116074]
- Novo Nordisk Fonden [NNF13OC0006239] Funding Source: researchfish
In most situations, the angiotensin AT2-receptor (AT2R) mediates physiological actions opposing those mediated by the AT1-receptor (AT1R), including a vasorelaxant effect. Nevertheless, experimental evidence vastly supports that systemic application of AT2R-agonists is blood pressure neutral. However, stimulation of AT2R locally within the brain or the kidney apparently elicits a systemic blood pressure lowering effect. A systemic effect of AT2R stimulation on blood pressure can also be achieved, when the prevailing effect of continuous background AT1R-stimulation is attenuated by low-dose AT1R blockade. Despite a lack of effect on blood pressure, AT2R stimulation still protects from hypertensive end-organ damage. Current data and evidence therefore suggest that AT2R agonists will not be suitable as future antihypertensive drugs, but that they may well be useful for end-organ protection in combination with established anti-hypertensives.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据